Melanoma Coverage from Every Angle
Advertisement
Advertisement

Ahmad A. Tarhini, MD, PhD, on Survival Benefits of Adjuvant Ipilimumab in High-Risk Melanoma

Posted: Tuesday, June 4, 2019

Ahmad A. Tarhini, MD, PhD, of Emory University and Winship Cancer Institute, discusses the United States Intergroup E1609 findings that support early systemic adjuvant therapy for high-risk melanoma vs high-dose interferon for resected disease.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.